We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on AMGN. Amgen Inc. (AMGN)’s share was ...

Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority review. Tarlatamab has been ...

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen Inc. (NASDAQ:AMGN ... potential for AMGN lies in its innovative oncology portfolio, especially its BITE platform, which is expected to lead to several new treatments in the coming years.

Amgen Inc. (NASDAQ:AMGN ... potential for AMGN lies in its innovative oncology portfolio, especially its BITE platform, which is expected to lead to several new treatments in the coming years.

During his time at Amgen, Dr. McIver led the efforts in maximizing the value of bispecific T-cell engager (BiTE) assets across multiple hematologic and solid tumor malignancies. Janux’s first ...